APHC1: sea-anemone peptide claim — RU2368621C1
Сергей Александрович Козлов (RU), Сергей Александрович Козлов, Ярослав Алексеевич Андреев (RU), Ярослав Алексеевич Андреев, Сергей Геннадьевич Кошелев (RU), Сергей Геннадьевич Кошелев, Екатерина Александровна Иванова (RU), Екатерина Александровна Иванова, Елена Владимировна Лейченко (RU), Елена Владимировна Лейченко, Эмма Павловна Козловская (RU), Эмма Павловна Козловская, Евгений Васильевич Гришин (RU), Евгений Васильевич Гришин · 2009 · RU2368621C1 · patent family 41169539
Published 2009-09-27.
Reported patent results
Reported findings
APHC1 produced partial, reversible channel inhibition and a delayed analgesic-like response in the mouse test.
APHC1 laboratory channel-response and small mouse analgesia experiments; one described mouse comparison has 5 animals per group.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Channel response | Maximum inhibition reported as 32 ± 9% on average, with a highest value of 50% | Partial, reversible inhibition; not complete channel blockade |
| Mouse analgesic time course | Effect developed over approximately 1–2 hours and lasted more than 2 hours | Small experimental assay; not human pain relief duration |
Cellular and animal findings do not establish clinical analgesic efficacy or safe use. The peptide is distinct from other marine channel families.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. The claim explicitly names APHC1 and defines the analgesic peptide.
A molecular claim is not proof of human analgesia. APHC peptides differ from HCRG21 and the Hcr ASIC research family.
- Publication
- RU2368621C1 ↗ · 2009-09-27
- Earliest priority / filing
- 2008-04-04 / 2008-04-04
- Original applicant / assignee
- Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41169539 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Actinia polypeptide having analgetic action
Inventors: Сергей Александрович Козлов (RU); Сергей Александрович Козлов; Ярослав Алексеевич Андреев (RU); Ярослав Алексеевич Андреев; Сергей Геннадьевич Кошелев (RU); Сергей Геннадьевич Кошелев; Екатерина Александровна Иванова (RU); Екатерина Александровна Иванова; Елена Владимировна Лейченко (RU); Елена Владимировна Лейченко; Эмма Павловна Козловская (RU); Эмма Павловна Козловская; Евгений Васильевич Гришин (RU); Евгений Васильевич Гришин.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A molecular claim is not proof of human analgesia. APHC peptides differ from HCRG21 and the Hcr ASIC research family.
- Cellular and animal findings do not establish clinical analgesic efficacy or safe use. The peptide is distinct from other marine channel families.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-41169539. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Сергей Александрович Козлов (RU), Сергей Александрович Козлов, Ярослав Алексеевич Андреев (RU), Ярослав Алексеевич Андреев, Сергей Геннадьевич Кошелев (RU), Сергей Геннадьевич Кошелев, Екатерина Александровна Иванова (RU), Екатерина Александровна Иванова, Елена Владимировна Лейченко (RU), Елена Владимировна Лейченко, Эмма Павловна Козловская (RU), Эмма Павловна Козловская, Евгений Васильевич Гришин (RU), Евгений Васильевич Гришин. APHC1: sea-anemone peptide claim — RU2368621C1 RU2368621C1 · patent family 41169539 2009.
Molekul research summary: https://molekul.io/research/patent-ru2368621c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry